Search results for "Harm"

showing 10 items of 13866 documents

Phenolic Composition of Hydrophilic Extract of Manna from Sicilian Fraxinus angustifolia Vahl and its Reducing, Antioxidant and Anti-Inflammatory Act…

2019

Manna, a very singular vegetable product derived from the spontaneous solidification of the sap of some Fraxinus species, has long been known for its mild laxative and emollient properties. In this work, a hydro-alcoholic extract of manna (HME) from Sicilian Fraxinus angustifolia Vahl was investigated using HPLC-DAD to find phenol components and using chemical and biological in vitro assays to determine its reducing, antioxidant and anti-inflammatory capacity. We identified elenolic acid, tyrosol, hydroxytyrosol, catechin, fraxetin, verbascoside, gallic acid, procyanidin-B1, and luteolin 3,7 glucoside, in order of abundance. Measurements of total antioxidant activity by Folin-Ciocalteu reac…

0301 basic medicinemanna bioactivityAntioxidantantioxidantPhysiologyDPPHmedicine.medical_treatmentClinical BiochemistryFraxinus angustifoliaPhytochemicalBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineLipid oxidation<i>Fraxinus</i>medicinereducing powerFraxinuFood scienceMolecular BiologyElenolic acidred blood cell oxidationbiologyintestinal bowel disease modellcsh:RM1-950Cell Biologybiology.organism_classificationphytochemicalsTyrosol030104 developmental biologylcsh:Therapeutics. Pharmacologychemistry030220 oncology & carcinogenesisHydroxytyrosolFraxetinmannaAntioxidants
researchProduct

Assessment of genetically modified maize NK603 x MON810 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐007)

2018

Efsa Panel On Genetically Modified Organisms (gmo)Scientific opinionRequestor:European Commission (DG SANTE)Question number:EFSA-Q-2017-00028; Following the submission of application EFSA-GMO-RX-007 under Regulation (EC) No 1829/2003 from Monsanto, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application of the herbicide-tolerant and insect-resistant genetically modified maize NK603 x MON810. The data received in the context of this renewal application contained post-market environmental monitoring reports, a systematic searc…

0301 basic medicinemaïsVeterinary (miscellaneous)gmo[SDV]Life Sciences [q-bio]2405 ParasitologyogmTP1-1185Plant SciencemaizeMicrobiologyzea mays03 medical and health sciences0404 agricultural biotechnology1110 Plant Sciencearticles 11 and 23TX341-6411106 Food ScienceNK603xMON8102. Zero hungerrenewal030109 nutrition & dieteticsNutrition. Foods and food supplymaize; NK603xMON810; renewal; articles 11 and 23; Regulation (EC) No1829/2003indian cornChemical technology2404 MicrobiologyRegulation (EC) No 1829/2003maize;NK603 x MON810;renewal;articles 11 and 23;Regulation (EC) No 1829/2003NK603 x MON81010079 Institute of Veterinary Pharmacology and Toxicology04 agricultural and veterinary sciences040401 food scienceSettore AGR/02 - Agronomia E Coltivazioni Erbacee3401 Veterinary (miscellaneous)Scientific OpinionSettore AGR/11 - Entomologia Generale E ApplicataRegulation (EC) No1829/2003570 Life sciences; biologyAnimal Science and ZoologyParasitology1103 Animal Science and ZoologyNK603 x MON810Regulation (EC) No 1829/2003Food Science
researchProduct

Strategies against nonsense: oxadiazoles as translational readthrough-inducing drugs (TRIDs)

2019

This review focuses on the use of oxadiazoles as translational readthrough-inducing drugs (TRIDs) to rescue the functional full-length protein expression in mendelian genetic diseases caused by nonsense mutations. These mutations in specific genes generate premature termination codons (PTCs) responsible for the translation of truncated proteins. After a brief introduction on nonsense mutations and their pathological effects, the features of various classes of TRIDs will be described discussing differences or similarities in their mechanisms of action. Strategies to correct the PTCs will be presented, particularly focusing on a new class of Ataluren-like oxadiazole derivatives in comparison …

0301 basic medicinemedia_common.quotation_subjectNonsenseNonsense mutationRegulatorSettore BIO/11 - Biologia MolecolareReviewComputational biologyBiologyOxadiazoleCatalysiscystic fibrosislcsh:ChemistryInorganic Chemistry03 medical and health sciences0302 clinical medicineAtalurenTranslational readthrough inducing drugsPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologyGeneSpectroscopymedia_commonNonsense mutationOrganic ChemistryTranslational readthroughoxadiazolesPremature termination codonTranslation (biology)General MedicineSettore CHIM/06 - Chimica OrganicaSmall moleculeSettore CHIM/08 - Chimica FarmaceuticaTransmembrane proteinComputer Science ApplicationsSettore BIO/18 - Genetica030104 developmental biologyPharmaceutical Preparationslcsh:Biology (General)lcsh:QD1-999Codon NonsenseProtein Biosynthesis030220 oncology & carcinogenesisCystic fibrosi
researchProduct

A new class of phenylhydrazinylidene derivatives as inhibitors of Staphylococcus aureus biofilm formation

2016

In the struggle against the emergence of the antibiotic resistance, new molecules targeting biofilm formation could be useful as adjuvant of conventional antibiotics. This study focused on a new class of 2-phenylhydrazinylidene derivatives as antivirulence agents. The compound 12e showed interesting activities against biofilm formation of all tested Staphylococcus aureus strains with IC50 ranging from 1.7 to 43 µM; compounds 12f and 13a resulted strong inhibitors of S. aureus ATCC 6538 and ATCC 29213 biofilm formation with IC50 of 0.9 and 0.8 µM, respectively. A preliminary study on the mechanism of action was carried on evaluating the inhibition of sortase A transpeptidase. Compound 12e re…

0301 basic medicinemedicine.drug_class030106 microbiologyAntibioticsBacterial adhesionAntibiofilm agentSettore BIO/19 - Microbiologia Generalemedicine.disease_causeMicrobiologyAntivirulence agent03 medical and health sciencesAntibiotic resistanceIn vivomedicineGeneral Pharmacology Toxicology and PharmaceuticsbiologyChemistrySortase AOrganic ChemistryBiofilmPhenylhydrazinylidene derivativebiochemical phenomena metabolism and nutritionbiology.organism_classificationSettore CHIM/08 - Chimica FarmaceuticaGalleria mellonellaSettore AGR/11 - Entomologia Generale E Applicata030104 developmental biologyMechanism of actionBiochemistryStaphylococcus aureusPharmacology Toxicology and Pharmaceutics (all)Sortase Amedicine.symptomMedicinal Chemistry Research
researchProduct

Prospecting for cytotoxic and antiprotozoal 4-aryl-4H-chromenes and 10-aryldihydropyrano[2,3-f]chromenes.

2018

Different studies reported that genetic predisposition or metabolic dysfunction are the risk factors for cancer. Infectious parasitic diseases were listed among factors that predispose to cancer. Because of the resemblance between the life cycle of cancer cells and some parasites, this study aimed to prepare pyran derivatives with cytotoxic and antiprotozoal potencies. Therefore, 7 chromenes, 10 pyranocoumarins, and an unexpected intermediate were obtained from a multi-reagent one-pot reaction. These compounds were evaluated for their cytotoxicity on sensitive and resistant leukemia cancer cells lines and against two protozoan parasites, namely Trypanosoma cruzi and Leishmania amazonensis a…

0301 basic medicinemedicine.drug_classAntiparasiticTHP-1 CellsTrypanosoma cruziAntiprotozoal AgentsPharmaceutical ScienceAntineoplastic AgentsApoptosisPharmacology03 medical and health sciencesStructure-Activity RelationshipParasitic Sensitivity TestsDrug DiscoverymedicineTumor Cells CulturedCytotoxic T cellHumansBenzopyransTrypanosoma cruziCytotoxicityAmastigoteCell ProliferationLeishmaniabiologyDose-Response Relationship DrugMolecular StructureChemistryCancerCell Cycle Checkpointsbiology.organism_classificationmedicine.disease030104 developmental biologyCancer cellAntiprotozoalDrug Screening Assays AntitumorArchiv der Pharmazie
researchProduct

Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.

2020

Epigenetic modifiers provide a new target for the development of anti-cancer drugs. The eraser histone deacetylase 6 (HDAC6) is a class IIb histone deacetylase that targets various non-histone proteins such as transcription factors, nuclear receptors, cytoskeletal proteins, DNA repair proteins, and molecular chaperones. Therefore, it became an attractive target for cancer treatment. In this study, virtual screening was applied to the MicroCombiChem database with 1162 drug-like compounds to identify new HDAC6 inhibitors. Five compounds were tested in silico and in vitro as HDAC6 inhibitors. Both analyses revealed 1-cyclohexene-1-carboxamide, 2-hydroxy-4,4-dimethyl-N-1-naphthalenyl-6-oxo- (MC…

0301 basic medicinemedicine.drug_classDNA repairAntineoplastic AgentsApoptosisHistone Deacetylase 6MicrotubulesEpigenesis Genetic03 medical and health sciences0302 clinical medicineCell MovementTubulinNeoplasmsCyclohexenesmedicineAnimalsHumansNeoplasm InvasivenessEpigeneticsHSP90 Heat-Shock ProteinsTranscription factorZebrafishPharmacologyChemistryHistone deacetylase inhibitorCell migrationAcetylationHDAC6Xenograft Model Antitumor AssaysCell biologyHistone Deacetylase Inhibitors030104 developmental biologyCell culture030220 oncology & carcinogenesisMCF-7 CellsHistone deacetylaseApoptosis Regulatory ProteinsPharmacological research
researchProduct

Superagonistic CD28 stimulation induces IFN‐γ release from mouse T helper 1 cells in vitro and in vivo

2020

Like human Th1 cells, mouse Th1 cells also secrete IFN-γ upon stimulation with a superagonistic anti-CD28 monoclonal antibody (CD28-SA). Crosslinking of the CD28-SA via FcR and CD40-CD40L interactions greatly increased IFN-γ release. Our data stress the utility of the mouse as a model organism for immune responses in humans.

0301 basic medicinemedicine.drug_classImmunologyved/biology.organism_classification_rank.speciesCD40 LigandStimulationchemical and pharmacologic phenomenaBiologyMonoclonal antibodyLymphocyte Activation03 medical and health sciencesInterferon-gammaMice0302 clinical medicineImmune systemCD28 AntigensIn vivomedicineImmunology and AllergyAnimalsHumansSecretionddc:610CD40 AntigensModel organismved/biologyCD28Antibodies Monoclonalhemic and immune systemsTh1 CellsIn vitroCell biology030104 developmental biology030215 immunologySignal Transduction
researchProduct

Evaluating ancient Egyptian prescriptions today: Anti-inflammatory activity of Ziziphus spina-christi.

2015

Abstract Background Ziziphus spina-christi (L.) Desf. (Christ's Thorn Jujube) is a wild tree today found in Jordan, Israel, Egypt, and some parts of Africa, which was already in use as a medicinal plant in Ancient Egypt. In ancient Egyptian prescriptions, it was used in remedies against swellings, pain, and heat, and thus should have anti-inflammatory effects. Nowadays, Z. spina-christi, is used in Egypt (by Bedouins, and Nubians), the Arabian Peninsula, Jordan, Iraq, and Morocco against a wide range of illnesses, most of them associated with inflammation. Pharmacological research undertaken to date suggests that it possesses anti-inflammatory, hypoglycemic, hypotensive and anti-microbial e…

0301 basic medicinemedicine.drug_classLeupeptinsIn silicoHerbal MedicineEgypt AncientAnti-Inflammatory AgentsPharmaceutical SciencePlant RootsAnti-inflammatory03 medical and health sciencesCell Line TumorDrug DiscoveryMedicineGallocatechinBioassayHumansElectrophoretic mobility shift assayHistory AncientPharmacologyZiziphus spina-christiInflammationPlants MedicinalbiologyTraditional medicinePlant Stemsbusiness.industryPlant ExtractsTranscription Factor RelAZiziphusZiziphusbiology.organism_classificationMolecular Docking Simulation030104 developmental biologyComplementary and alternative medicineDocking (molecular)SeedsMolecular MedicinebusinessPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies

2021

Therapeutic targeting of blood coagulation is a challenging task as it interferes with the delicate balance of pro- and anticoagulant activities. Anticoagulants are employed in millions of thrombophilic patients worldwide each year. The treatment and prevention of venous thromboembolism has changed drastically. Traditional vitamin K antagonists are being replaced by direct oral anticoagulants (DOACs), which selectively target coagulation factors Xa or IIa. However for a growing population with comorbidities satisfying therapeutic options are still lacking and the quest for novel therapeutics continues. Recently, targeting factors XI or XII have emerged as new therapeutic strategies. As thes…

0301 basic medicinemedicine.drug_classPopulationVitamin kBioinformaticsTherapeutic targeting03 medical and health sciences0302 clinical medicinemicroRNAHumansMedicinePharmacology (medical)educationFactor XIPharmacologyHemostasiseducation.field_of_studybusiness.industryAnticoagulantAnticoagulantsThrombosisMicroRNAs030104 developmental biologyCoagulation030220 oncology & carcinogenesisHemostasisbusinessVenous thromboembolismPharmacology &amp; Therapeutics
researchProduct

Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management

2017

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that is caused by an autoimmune response against central nervous system (CNS) structures. Traditionally considered a T-cell-mediated disorder, the contribution of B cells to the pathogenesis of MS has long been debated. Based on recent promising clinical results from CD20-depleting strategies by three therapeutic monoclonal antibodies in clinical phase II and III trials (rituximab, ocrelizumab and ofatumumab), targeting B cells in MS is currently attracting growing interest among basic researchers and clinicians. Many questions about the role of B and plasma cells in MS remain still unanswered, ranging from the role of…

0301 basic medicinemedicine.drug_classReviewsDiseaseMonoclonal antibodyOfatumumablcsh:RC346-429Pathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicinelcsh:Neurology. Diseases of the nervous systemPharmacologybusiness.industryMultiple sclerosismedicine.diseaseRegimen030104 developmental biologyNeurologychemistryImmunologyRituximabOcrelizumabNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct